The DOI matches its Crossref record.
Cyclic lactam .alpha.-melanotropin analogs of Ac-Nle4-cyclo[Asp5,D-Phe7,Lys10]-.alpha.-melanocyte-stimulating hormone-(4-10)-NH2 with bulky aromatic amino acids at position 7 show high antagonist potency and selectivity at specific melanocortin receptors
Open accessAbstract
The cloning of the melanocyte-stimulating hormone (MSH) and adrenocorticotropic hormone (ACTH) receptors (MC1-R and MC2-R, respectively) recently has led to the identification of three additional melanocortin receptors, MC3-R, MC4-R, and MC5-R. The MC2 receptor primarily recognizes only ACTH peptides, but the other four receptors all recognize alpha-melanocyte-stimulating hormone (alpha-MSH) and potent alpha-MSH agonists such as [Nle4,D-Phe7]alpha-MSH-NH2 and Ac-Nle4-c[Asp5,D-Phe7,Lys10]alpha-MSH-(4-10)-NH2 as well as ACTH. The absence of any known physiological role for these new receptors, expressed both in the brain (MC3-R and MC4-R) and throughout a number of peripheral tissues (MC5-R), has necessitated as search for potent and receptor selective agonists and antagonists. We report here that analogues of the superpotent cyclic agonist analogue Ac-Nle4-c[Asp5,D-Phe7, Lys10]alpha-MSH-(4-10)-NH2, in which a bulky aromatic amino acid is substituted in the 7-position, can produce potent and selective antagonists for melanocortin receptors. Thus, the D-p-iodophenylalanine7-containing analogue Ac-Nle4-c[Asp5,D-Phe(pI)7,Lys10]alpha-MSH-(4-10)-NH2 is a potent antagonist (pA2 = 10.3) in the classical frog skin (Rana pipiens) assay (MC1-R), as is the D-2'-naphthylalanine7 (D-Nal(2)7)-containing analogue Ac-Nle4-c[Asp5,D-Nal(2)7,Lys10]alpha-MSH-(4-10)-NH2 (pA2 > 10.3). Interestingly, the D-p-chloro- and D-p-fluorophenylalanine7-containing analogues lacked antagonist activities at all melanotropin receptors, and both exhibited full agonist potency in the frog skin assay. The activity of these analogues also was examined at four mammalian melanocortin receptors. Interestingly, Ac-Nle4-c[Asp5,(D-Nal(2)7,Lys10] alpha-MSH-(4-10)-NH2 was found to be a potent antagonist of the MC4-R (pA2 = 9.3) with minimal agonist activity, a less potent antagonist of the MC3-R (pA2 = 8.3) with minimal agonist activity, and a full agonist of the MC1 and MC5 receptors. Surprisingly, Nle4-c[Asp5,D-Phe(pI)7,Lys10]alpha-MSH was found to be a potent agonist at the cloned human MC1-R (EC50 = 0.055 nM) and mouse MC1-R (EC50 = 0.19 nM) but had potent antagonist activities at the human MC4-R (pA2 = 9.7) and human MC3-R (pA2 = 8.3) with significant partial agonist activities (EC50 = 0.57 and 0.68 nM, respectively) as well. Thus, highly potent and receptor selective antagonist analogues can arise from substitution of the D-Phe7 residue with a bulky aromatic amino acid. These analogues can be used to help determine the functional roles of these receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Targeted disruption of the melanocortin-4 receptor results in obesity in mice
Huszar, D., Lynch, C. A., Fairchild-Huntress, V., Dunmore, J. H., Fang, Q., Berkemeier, L. R., Gu, W., Kesterson, R. A., Boston, B. A., Cone, R. D., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)81865-6 · Cited by 3,030
Self-citationRole of melanocortinergic neurons in feeding and the agouti obesity syndrome
Fan, W., Boston, B. A., Kesterson, R. A., Hruby, V. J., & Cone, R. D. (1997) · Nature · doi:10.1038/385165a0 · Cited by 1,902
Self-citationChen, A. S., Marsh, D. J., Trumbauer, M. E., Frazier, E. G., Guan, X.-M., Yu, H., Rosenblum, C. I., Vongs, A., Feng, Y., Cao, L., et al. (2000) · Nature Genetics · doi:10.1038/79254 · Cited by 894
Integration of NPY, AGRP, and Melanocortin Signals in the Hypothalamic Paraventricular Nucleus
Cowley, M. A., Pronchuk, N., Fan, W., Dinulescu, D. M., Colmers, W. F., & Cone, R. D. (1999) · Neuron · doi:10.1016/s0896-6273(00)80829-6 · Cited by 617
Self-citationStudies on the Physiological Functions of the Melanocortin System
Cone, R. D. (2006) · Endocrine Reviews · doi:10.1210/er.2006-0034 · Cited by 615
Self-citationResponse of melanocortin–4 receptor–deficient mice to anorectic and orexigenic peptides
Marsh, D. J., Hollopeter, G., Huszar, D., Laufer, R., Yagaloff, K. A., Fisher, S. L., Burn, P., & Palmiter, R. D. (1999) · Nature Genetics · doi:10.1038/5070 · Cited by 542
The Melanocortin-4 Receptor: Physiology, Pharmacology, and Pathophysiology
Tao, Y.-X. (2010) · Endocrine Reviews · doi:10.1210/er.2009-0037 · Cited by 531
Targeting melanocortin receptors as a novel strategy to control inflammation
Catania, A., Gatti, S., Colombo, G., & Lipton, J. M. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.1.1 · Cited by 438
AgRP(83-132) Acts as an Inverse Agonist on the Human-Melanocortin-4 Receptor
Nijenhuis, W. A. J. (2001) · Molecular Endocrinology · doi:10.1210/me.15.1.164 · Cited by 406
The Central Melanocortin System and Energy Homeostasis
Cone, R. D. (1999) · Trends in Endocrinology & Metabolism · doi:10.1016/s1043-2760(99)00153-8 · Cited by 350
Self-citationCholecystokinin-mediated suppression of feeding involves the brainstem melanocortin system
Fan, W., Ellacott, K. L. J., Halatchev, I. G., Takahashi, K., Yu, P., & Cone, R. D. (2004) · Nature Neuroscience · doi:10.1038/nn1214 · Cited by 307
Self-citationGrill, H. J., Ginsberg, A. B., Seeley, R. J., & Kaplan, J. M. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-23-10128.1998 · Cited by 278
Haskell-Luevano, C., & Monck, E. K. (2001) · Regulatory Peptides · doi:10.1016/s0167-0115(01)00234-8 · Cited by 252
Comparative Anatomy and Physiology of Pigment Cells in Nonmammalian Tissues
Bagnara, J. T., & Matsumoto, J. (2006) · The Pigmentary System · doi:10.1002/9780470987100.ch2 · Cited by 211
Panaro, B. L., Tough, I. R., Engelstoft, M. S., Matthews, R. T., Digby, G. J., Møller, C. L., Svendsen, B., Gribble, F., Reimann, F., Holst, J. J., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.10.004 · Cited by 179
Self-citationLi, S.-J., Varga, K., Archer, P., Hruby, V. J., Sharma, S. D., Kesterson, R. A., Cone, R. D., & Kunos, G. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-16-05182.1996 · Cited by 152
Self-citationWatts, A. G., Sanchez-Watts, G., & Kelly, A. B. (1999) · The Journal of Neuroscience · doi:10.1523/jneurosci.19-14-06111.1999 · Cited by 102
Melanocortins and cardiovascular regulation
Versteeg, D. H. G., Van Bergen, P., Adan, R. A. H., & De Wildt, D. J. (1998) · European Journal of Pharmacology · doi:10.1016/s0014-2999(98)00615-3 · Cited by 98
Interactions of Human Melanocortin 4 Receptor with Nonpeptide and Peptide Agonists,
Pogozheva, I. D., Chai, B.-X., Lomize, A. L., Fong, T. M., Weinberg, D. H., Nargund, R. P., Mulholland, M. W., Gantz, I., & Mosberg, H. I. (2005) · Biochemistry · doi:10.1021/bi0501840 · Cited by 92
The Neuroendocrine Circuitry Controlled by POMC, MSH, and AGRP
Biebermann, H., Kühnen, P., Kleinau, G., & Krude, H. (2012) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-642-24716-3_3 · Cited by 70
γ-MSH, sodium metabolism, and salt-sensitive hypertension
Humphreys, M. H. (2004) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00365.2003 · Cited by 51
Design of cyclic and other templates for potent and selective peptide α-MSH analogues
Fung, S., & Hruby, V. J. (2005) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2005.06.010 · Cited by 44
Development of potent selective competitive-antagonists of the melanocortin type 2 receptor
Bouw, E., Huisman, M., Neggers, S. J. C. M. M., Themmen, A. P. N., van der Lely, A. J., & Delhanty, P. J. D. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.07.003 · Cited by 22
Adank, D. N., Lunzer, M. M., Lensing, C. J., Wilber, S. L., Gancarz, A. M., & Haskell-Luevano, C. (2018) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00330 · Cited by 18
Metadata
- Authors
- Hrubu, V. J., Lu, D., Sharma, S. D., de L. Castrucci, A., Kesterson, R. A., Al-Obeidi, F. A., Hadley, M. E., & Cone, R. D.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1995-09
- Volume
- 38
- Issue
- 18
- Pages
- 3454-3461
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2015370922
- Cited by
- 348
- References
- 0
- FWCI
- 4.32
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.